Anti-Coagulants - United Kingdom

United Kingdom

The Anti-Coagulants market in the United Kingdom is expected to reach a projected revenue of US$0.95bn in 2024.
This market is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 8.37%, leading to a market volume of US$1.42bn by 2029.
When compared globally, United States is predicted to generate the highest revenue in this market, with US$16,740.00m in 2024.
The United Kingdom has seen a significant increase in the adoption of novel oral anticoagulants, with healthcare professionals favoring their ease of use and improved patient compliance.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in United Kingdom is experiencing steady growth, driven by several factors that are unique to the region.

Customer preferences: The demand for Anti-Coagulants in the United Kingdom is driven by an aging population and an increase in lifestyle-related diseases such as obesity, diabetes, and hypertension. Additionally, the high incidence of cardiovascular diseases and the increasing prevalence of stroke are major drivers of the market.

Trends in the market: The Anti-Coagulants market in the United Kingdom is experiencing a shift towards novel oral anticoagulants (NOACs) due to their advantages over traditional anticoagulants. NOACs have a lower risk of bleeding and do not require regular monitoring, making them more convenient for patients. The market is also experiencing consolidation, with major players acquiring smaller companies to expand their product portfolio.

Local special circumstances: The United Kingdom has a well-established healthcare system, with the National Health Service (NHS) providing healthcare to the majority of the population. This has led to a high volume of prescriptions for Anti-Coagulants, making the market highly regulated. Additionally, Brexit has created uncertainty in the market, with potential changes to regulations and trade agreements affecting the industry.

Underlying macroeconomic factors: The United Kingdom's economy has been affected by the COVID-19 pandemic, with a decline in GDP and increased government debt. This has led to a potential decrease in healthcare spending and a shift towards cost-effective treatments. However, the aging population and high prevalence of lifestyle-related diseases are expected to continue driving demand for Anti-Coagulants in the long term.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.